Terminology Service for NFDI4Health
JSON

Fresolimumab

Go to external page http://purl.obolibrary.org/obo/NCIT_C63546

A pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) -beta 1, 2 and 3 with potential antineoplastic activity. Fresolimumab binds to and inhibits the activity of all isoforms of TGF-beta, which may result in the inhibition of tumor cell growth, angiogenesis, and migration. TGF-beta, a cytokine often over-expressed in various malignancies, may play an important role in promoting the growth, progression, and migration of tumor cells. [ ]

Term info

Label

Fresolimumab

Synonyms
  • Anti-TGF-Beta Monoclonal Antibody GC1008
  • FRESOLIMUMAB
  • Fresolimumab
  • GC1008
  • Human Anti-TGF-Beta Monoclonal Antibody GC1008
  • Immunoglobulin G4, anti-(transforming growth factor beta) (human monoclonal GC-1008 heavy chain), disulfide with human monoclonal GC-1008 light chain, Dimer
  • anti-TGF-beta monoclonal antibody GC1008
Subsets

NCIT_C116978, NCIT_C63923, NCIT_C128784, NCIT_C157711, NCIT_C116977, NCIT_C157712

ALT DEFINITION

A monoclonal antibody being studied in the treatment of kidney cancer, melanoma, and pulmonary fibrosis. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Anti-TGF-beta monoclonal antibody GC1008 binds to the protein transforming growth factor-beta (TGF?) and may block the growth of cancer cells that make it.

Accepted Therapeutic Use For

Idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, and cancer

CAS Registry

948564-73-6

Display Name

Fresolimumab

FDA UNII Code

375142VBIA

Has Target

http://purl.obolibrary.org/obo/NCIT_C20455

Legacy Concept Name

Anti-TGF-Beta_Monoclonal_Antibody_GC1008

Preferred Name

Fresolimumab

Semantic Type

Amino Acid, Peptide, or Protein, Immunologic Factor

UMLS CUI

C2987643

code

C63546